Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

Inclusion Criteria:

   - Parts A-C only: Patients must have biopsy proven MF, clinical stage I, II, or III
   (excluding visceral or nodal involvement), and must be refractory to or intolerant of
   established therapies for their condition

   - Part D only: Patients diagnosed with CLL who are intolerant to, or have disease that
   is relapsed/refractory after, at least two prior therapies

   - Part E only: Patients with biopsy-proven DLBCL who are intolerant to, or have disease
   that is relapsed/refractory after, at least two prior therapies, including any
   anti-CD20 monoclonal antibody and chemotherapy with curative intent

   - Part F only: Patients with documented HTLV-1 infection and histologically or
   cytologically proven ATLL of any stage, and who are intolerant to, or have disease
   that is relapsed/refractory after, at least one prior therapy

   - Females must not be pregnant or lactating. Women of child-bearing potential must use a
   highly effective method of contraception throughout their study participation and for
   at least 6 months following the last dose of study drug.

   - Males must be surgically sterile, abstinent, or if engaged in sexual relations with a
   female of child-bearing potential, must be willing to use a highly effective method of
   contraception throughout their study participation and for at least 6 months after the
   last dose of study drug.

Exclusion Criteria:

   - Evidence of renal or liver dysfunction at screening

   - Clinically significant anemia, neutropenia or thrombocytopenia at screening

   - History of bleeding diathesis or coagulopathy

   - Clinically significant cardiovascular disease, history of myocardial infarction within
   the last 6 months, or evidence of QTc interval prolongation at screening

   - Serologically positive for HIV; serologically positive for Hepatitis B or Hepatitis C
   with evidence of liver dysfunction or documented liver cirrhosis

   - Prior malignancies within the past 3 years (with allowance for adequately treated in
   situ carcinoma of the cervix uteri, and basal cell or localized squamous cell
   carcinoma of the skin treated with curative intent)

   - Use of an investigational small molecule drug during the 30 days prior to screening or
   use of an investigational oligonucleotide or biologic drug during the prior 90 days